Patents by Inventor Anton P. McCaffrey
Anton P. McCaffrey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240140982Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: September 14, 2023Publication date: May 2, 2024Applicant: TriLink Biotechnologies, LLCInventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Patent number: 11878991Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7 Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: November 6, 2020Date of Patent: January 23, 2024Assignee: TriLink BioTechnologies, LLCInventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Patent number: 11578095Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: May 26, 2022Date of Patent: February 14, 2023Assignee: TriLink Biotechnologies, LLCInventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Publication number: 20220289786Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: May 26, 2022Publication date: September 15, 2022Applicant: TriLink Biotechnologies, LLCInventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Patent number: 11414453Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: August 2, 2021Date of Patent: August 16, 2022Assignee: TriLink Biotechnologies, LLCInventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Publication number: 20210371452Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: August 2, 2021Publication date: December 2, 2021Applicant: TriLink Biotechnologies, LLCInventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Publication number: 20210261597Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7 Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: November 6, 2020Publication date: August 26, 2021Applicant: TriLink Biotechnologies, LLCInventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Patent number: 10913768Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: September 20, 2016Date of Patent: February 9, 2021Assignee: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Patent number: 10519189Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: December 26, 2018Date of Patent: December 31, 2019Assignee: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Patent number: 10494399Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: April 1, 2019Date of Patent: December 3, 2019Assignee: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Publication number: 20190270766Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: April 1, 2019Publication date: September 5, 2019Applicant: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Publication number: 20190144490Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: December 26, 2018Publication date: May 16, 2019Applicant: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Publication number: 20180273576Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: September 20, 2016Publication date: September 27, 2018Applicant: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Patent number: 8685937Abstract: The present invention relates to optimized aptamers and methods of using these aptamers.Type: GrantFiled: August 6, 2009Date of Patent: April 1, 2014Assignee: University of Iowa Research FoundationInventors: Paloma H. Giangrande, James O. McNamara, Anton P. McCaffrey
-
Publication number: 20120297495Abstract: Embodiments of the present invention provide methods for targeted inactivation of viral genomes. In one embodiment, zinc-finger proteins in which DNA binding sites are altered such that they recognize and bind different, desired DNA sequences contained in hepatitis B virus (HBV) and that include nuclease domains are used for inactivation. Other embodiments for targeted inactivation of viral genomes use small nucleic acid molecules, such as short micro-RNA molecules or short hairpin RNA molecules capable of mediating RNA interference (RNAi) against the hepatitis B virus.Type: ApplicationFiled: June 12, 2012Publication date: November 22, 2012Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Anton P. McCaffrey, Thomas J. Cradick
-
Patent number: 8232257Abstract: Embodiments of the present invention provide methods for targeted inactivation of viral genomes. In one embodiment, zinc-finger proteins in which DNA binding sites are altered such that they recognize and bind different, desired DNA sequences contained in hepatitis B virus (HBV) and that include nuclease domains are used for inactivation. Other embodiments for targeted inactivation of viral genomes use small nucleic acid molecules, such as short micro-RNA molecules or short hairpin RNA molecules capable of mediating RNA interference (RNAi) against the hepatitis B virus.Type: GrantFiled: March 27, 2008Date of Patent: July 31, 2012Assignee: University of Iowa Research FoundationInventors: Anton P. McCaffrey, Thomas J. Cradick
-
Publication number: 20120014875Abstract: The present invention relates to optimized aptamers and methods of using these aptamers.Type: ApplicationFiled: August 6, 2009Publication date: January 19, 2012Applicant: University of Iowa Research FoundationInventors: Paloma H. Giangrande, James O. McNamara, Anton P. McCaffrey
-
Publication number: 20100235936Abstract: Embodiments of the present invention provide methods for targeted inactivation of viral genomes. In one embodiment, zinc-finger proteins in which DNA binding sites are altered such that they recognize and bind different, desired DNA sequences contained in hepatitis B virus (HBV) and that include nuclease domains are used for inactivation. Other embodiments for targeted inactivation of viral genomes use small nucleic acid molecules, such as short micro-RNA molecules or short hairpin RNA molecules capable of mediating RNA interference (RNAi) against the hepatitis B virus.Type: ApplicationFiled: March 27, 2008Publication date: September 16, 2010Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Anton P. McCaffrey, Thomas J. Cradick